Hostname: page-component-78c5997874-94fs2 Total loading time: 0 Render date: 2024-11-18T18:33:07.452Z Has data issue: false hasContentIssue false
  • English
  • Français

Mechanism of Action of Trazodone: a Multifunctional Drug

Published online by Cambridge University Press:  07 November 2014

Stephen M. Stahl
Get access Rights & Permissions [Opens in a new window]

Extract

Multifunctional drugs are those with more than one therapeutic mechanism. Trazodone is a multifunctional drug with dose-dependent pharmacologic actions. That is, it has hypnotic actions at low doses due to blockade of 5-HT2A receptors, as well as H1 histamine receptors and α1 adrenergic receptors. Higher doses recruit the blockade of the serotonin transporter (SERT) and turn trazodone into an antidepressant. Although trazodone has traditionally been used as a low dose hypnotic, a new controlled release formulation that has the potential to improve the tolerability of high doses may provide an opportunity to revisit this multifunctional drug as an antidepressant as well.

Type
Trends in Psychopharmacology
Information
CNS Spectrums , Volume 14 , Issue 10 , October 2009 , pp. 536 - 546
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Stahl, SM. Multifunctional Drugs: A Novel Concept for Psychopharmacology. CNS Spectr. 2009;14:71–73.Google Scholar
2.Kim, DH, Maneen, MJ, Stahl, SM. Building a Better Antipsychotic: Receptor Targets for the Treatment of Multiple Symptom Dimensions of Schizophrenia. Neurotherapeutics. 2009;6:78–85.CrossRefGoogle ScholarPubMed
3.Van der Schyf, CJ, Youdim, MB. Multifunctional Drugs as Neurotherapeutics. Neurotherapeutics. 2009;6:1–3.Google Scholar
4.Millan, MJ, Dual and triple acting agents for treating core and comorbid symptoms of major depression: novel concept, new drugs. Neurotherapeutics. 2009;6:53–77.CrossRefGoogle ScholarPubMed
5.Stahl, SM. Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines. CNS Spectr. 2008;13:1027–1038.Google Scholar
6.Cusack, B, Nelson, A, Richelson, E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology(Berl). 1994;114:559–564.Google Scholar
7.Tatsumi, M, Groshan, K, Blakely, RD, Richelson, E. Pharmacological profile of anti-depressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340:249–258.CrossRefGoogle Scholar
8.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generations compounds. Life Sci. 2000;68:29–39.Google Scholar
9.Stahl, SM. Stahl's Essential Psychopharmacology. 3rd ed. New York, NY: Cambridge University Press; 2008Google Scholar
10.Owens, MJ, Morgan, WN, Plott, SJ, Nemeroff, CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther. 1997;283:1305–1322.Google ScholarPubMed
11.Knight, AR, Misra, A, Quirk, K, et al.Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:114–123.Google Scholar
12.Millan, MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005;60:441–460.Google Scholar
13.Dekeyne, A, Mannoury la Cour, C, et al.S32006, a novel 5HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology(Berl). 2008;199:549–568.Google Scholar
14.Rosenzweig-Lipson, S, Sabb, A, Stack, G, et al.Antidepressant like effects of the novel, selective 5HT2C receptor agonist WAY-163909 in rodents; Psychopharmacology(Berl). 2007;192:159–170CrossRefGoogle ScholarPubMed
15.Stahl, SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007;10:575–578.CrossRefGoogle ScholarPubMed
16.Maes, M, Westenberg, H, Vandoolaeghe, E, et al.Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine. J Clin Psychopharmacol. 1997;17:358–364.CrossRefGoogle ScholarPubMed
17.Raffa, RH, Shank, RP, Vaught, JL. Etioperidone, trazodone and mCPP: in vitro and in vivo identification of serotonin 5HT1A (antagonistic) activity. Psychopharmacology(Berl). 1992;108:320–326.CrossRefGoogle ScholarPubMed
18.Schoeffter, P, Hoyer, D. Interaction of arylpiperazines with 5HT1A, 5HT1B, 5HT1C and 5HT1D receptors: do discriminatory 5HT1B receptor ligands exist. Naunyn Schmiedebergs Arch Pharmacol. 1989;339:675–683.Google Scholar
19.Sills, MA, Wolfe, BB, Frazer, A. Determination of selective and non-selective compounds for the 5HT1A and 5HT1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther. 1984:231:480–487.Google Scholar
20.Conn, PJ, Sanders-Buse, E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic 5HT2 and 5HT1C receptors. J Pharmacol Exp Ther. 1987;242:552–557.Google Scholar
21.Cheng, FC, Tsai, TH, Wu, YS, Kuo, JS, Chen, CF. Pharmacokinetic and pharmacodynamic analyses of trazodone in rat striatum by in vivo microdialysis. J Pharm Biomed Anal. 1999;19:293–300.Google Scholar
22.Mihara, K, Yasui-Furukori, N, Kondo, T, et al.Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit. 2002;24:563–566.Google Scholar
23.Stahl, SM. Stahls Essential Psychopharmacology Prescribers Guide. 3rd ed. New York, NY: Cambridge University Press; 2009.Google Scholar
24. Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year (EPLILONG). Available at: http://clinicaltrials.gov/ct2/show/NCT00253903. Accessed:Google Scholar
25.Saper, CB, Chou, TC, Scammell, TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci. 2001;24:726–731.CrossRefGoogle ScholarPubMed
26.Shigemoto, Y, Fujii, Y, Shinomiya, K, Kamei, C. Participation of histaminergic H1 and noradrenergic alpha 1 receptors in orexin A-induced wakefulness in rats. Brain Res. 2004;1023:121–125.Google Scholar
27.Pazzagli, M, Gionvannini, MG, Pepeu, G. Traodone increases extracellular serotonin levels in the frontal cortex of rats, Eur J Pharmacol. 1999;383:249–257.Google Scholar
28.Marek, GJ, Carpenter, LL, McDougle, CJ, Price, LH. Synergistic action of 5HT2A antagonists and selectve serotonin reuptake inhibitors in neuropsychiatric disorders. Neuropsychopharmacology. 2003;28:402–412.Google Scholar
29.Cremers, T, Rea, K, Bosker, FJ, et al.Augmentation of SSRI effects on serotonin by 5HT2C antagonists: mechanistic studies. Neuropsychopharmacology. 2007;32:1550–1557.Google Scholar
30.Nierenberg, AA, Cole, JO, Glass, L. Possible trazodone potentiation of fluoxetine: a case series. J Clin Psychiatry. 1992;53:83–85.Google ScholarPubMed
31.DiMatteo, V, DeBlasi, A, DiGiulio, C, Esposito, E. Role of 5HT2C receptors in the control of central dopamine function. Trends Pharmacol Sci. 2001;22:229–232.CrossRefGoogle Scholar
32.DeDeurwaerdere, P, Navailles, S, Berg, KA, Claarke, WP, Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci. 2004;24:3235–3241.Google Scholar
33.Alex, KD, Pehek, EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther. 2007;113:296–320.CrossRefGoogle ScholarPubMed
34.Alex, KD, Yavanian, GJ, McFarlane, HG, Pluto, CP, Pehek, EA. Modulation of dopamine release by striatal 5HT2C receptors. Synapse. 2005;55:242–251.Google Scholar
35.Porras, G, DiMatteo, V, Fracasso, C, et al.5HT2A and 5HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum. Neuropsychopharmacology. 2002;26:311–324.Google Scholar
36.Santana, N, Bortolozzi, A, Serrats, J, Guadalupe, M, Artigas, F. Expression of serotonin 1A and serotonin 2A receptor in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex. 2004;14:1100–1109.CrossRefGoogle Scholar
37.Invemizzi, RW, Pierucci, M, Calcagno, E, et al.Selective activation of 5HT2C receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulate: a combined in vivo electrophysiological and neurochemical study. Neuroscience. 2007;144:1523–1535.Google Scholar
38.Abi-Saab, WM, Bubser, M, Roth, RH, Deutch, AY. 5HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology. 1999;20:92–96.CrossRefGoogle ScholarPubMed
39.Lemaire, V, Benquet, C, LeGarrec, D, Robertson, Sy, Smith, D, Stahl, SM, Modeling and simulation to optimize efficacy and tolerability for once a day trazodone formulation. Abstract presented at: The European College of Neuropsychopharmacology meeting; September 12-16, 2009; Istanbul, Turkey.CrossRefGoogle Scholar
40.Monteleone, P, Gnocchi, G, Delrio, G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol. 1989;9:284–287.CrossRefGoogle ScholarPubMed
41.Sheehan, DV, Croft, HA, Gossen, R, et al.Extended release trazodone in major depressive disorder: a randomized, double blind, placebo-controlled study. Psychiatry (Edgemont). 2009;6:20–33.Google Scholar
42.Gartlehner, G, Gaynes, BN, Hansen, RA, et al.Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149:734–750.CrossRefGoogle ScholarPubMed
43.Papakostas, GI, Fava, M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007;22:444–447.Google Scholar